Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 TrialBernard Zinman, Kuninobu Takai, Stewart B. Harris et al.|Diabetes Care|2019Cited by 282
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsVanita R. Aroda, Ildiko Lingvay, Andrew Ahmann et al.|Diabetes & Metabolism|2019Cited by 281